Skip to main content

Advertisement

SpringerLink
Log in

Reply to “Is there a promising role of HIPEC in patients with advanced mucinous ovarian cancer?” by lavazzo et al

  • Correspondence
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

The Original Article was published on 08 June 2020

A Gynecologic Oncology to this article was published on 17 March 2020

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Iavazzo C, Spiliotis J (2020) Is there a promising role of HIPEC in patients with advanced mucinous ovarian cancer? Arch Gynecol Obstet. https://doi.org/10.1007/s00404-020-05636-w

    Article  PubMed  Google Scholar 

  2. Nasioudis D, Albright BB, Ko EM et al (2020) Advanced stage primary mucinous ovarian carcinoma. Where do we stand? Arch Gynecol Obstet 301(4):1047–1054

    Article  CAS  Google Scholar 

  3. Kurnit KC, Sinno AK, Fellman BM et al (2019) Effects of gastrointestinal-type chemotherapy in women with ovarian mucinous carcinoma. Obstet Gynecol 134(6):1253–1259

    Article  Google Scholar 

  4. Mercier F, Bakrin N, Bartlett DL et al (2018) Peritoneal carcinomatosis of rare ovarian origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a multi-institutional cohort from PSOGI and BIG-RENAPE. Ann Surg Oncol 25(6):1668–1675

    Article  Google Scholar 

  5. Gore ME, Hackshaw A, Brady WE et al (2015) Multicentre trial of carboplatin/paclitaxel versus oxaliplatin/capecitabine, each with/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC). As presented at the 2015 ASCO Annual Meeting. https://meetinglibrary.asco.org/content/145864-156 (abstract 5528)

  6. Sato N, Saga Y, Mizukami H et al (2012) Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations. Oncol Rep 27(5):1336–1340

    CAS  PubMed  Google Scholar 

  7. McAlpine JN, Wiegand KC, Vang R et al (2009) HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 9:433

    Article  Google Scholar 

  8. Matsuo K, Nishimura M, Bottsford-Miller JN et al (2011) Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res 17(16):5367–5378

    Article  CAS  Google Scholar 

  9. Inaba K, Oda K, Aoki K et al (2016) Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging. Oncotarget 7(20):29577–29591

    Article  Google Scholar 

  10. Gorringe KL, Cheasley D, Wakefield MJ et al (2020) Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol 156(3):552–560

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, University of Pennsylvania Health System, 3400 Spruce Street, 1 West Gates, Philadelphia, PA, 19104, USA

    Dimitrios Nasioudis & Nawar A. Latif

Authors
  1. Dimitrios Nasioudis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nawar A. Latif
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DN: manuscript writing/editing. NAL: supervision, manuscript writing/editing.

Corresponding author

Correspondence to Dimitrios Nasioudis.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nasioudis, D., Latif, N.A. Reply to “Is there a promising role of HIPEC in patients with advanced mucinous ovarian cancer?” by lavazzo et al. Arch Gynecol Obstet 303, 599–600 (2021). https://doi.org/10.1007/s00404-020-05647-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-020-05647-7

Search

Navigation